Overview

Rituximab and ABVD for Hodgkin's Patients

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
0
Participant gender:
All
Summary
Primary Objective: - To determine the feasibility, toxicity, and efficacy of Rituximab with standard dose ABVD combination chemotherapy. ABVD combination chemotherapy consists of Adriamycin, Bleomycin, Vinblastine and DTIC.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genentech, Inc.
Treatments:
Bleomycin
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Rituximab
Vinblastine
Criteria
Inclusion Criteria:

1. Hodgkin's disease patients who relapse after radiation therapy alone and previously
untreated patients with stage II bulky, III and IV who are eligible for ABVD.

2. Must have histologically proven diagnosis of Hodgkin's disease (Nodular sclerosis or
mixed cellularity).

3. Must have bidimensionally measurable disease.

4. Must sign a consent form.

5. Must be older than 16 years of age.

6. Must have adequate bone marrow reserve (ANC > 1,000/microL, Platelet > 100,000/microL

7. Left Ventricular Ejection Fraction (LVEF) >/= 50% by multigated acquisition (MUGA)
scan or echocardiogram.

8. Serum creatinine < 2 mg/dl, serum bilirubin < 2 mg/dl

Exclusion Criteria:

1. HIV positive.

2. Pregnant women and women of child bearing age who are not practicing adequate
contraception.

3. Prior chemotherapy.

4. Severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and
asthma.